conivaptan has been researched along with thalidomide in 3 studies
Studies (conivaptan) | Trials (conivaptan) | Recent Studies (post-2010) (conivaptan) | Studies (thalidomide) | Trials (thalidomide) | Recent Studies (post-2010) (thalidomide) |
---|---|---|---|---|---|
188 | 17 | 64 | 9,789 | 1,385 | 4,342 |
Protein | Taxonomy | conivaptan (IC50) | thalidomide (IC50) |
---|---|---|---|
Cereblon isoform 4 | Magnetospirillum gryphiswaldense | 7.8 | |
Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.37 | |
Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 0.5 | |
DNA damage-binding protein 1 | Homo sapiens (human) | 1.38 | |
Protein cereblon | Homo sapiens (human) | 1.38 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Hussar, DA | 1 |
1 review(s) available for conivaptan and thalidomide
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for conivaptan and thalidomide
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
New drugs 07, part I.
Topics: Abatacept; Acetanilides; Alprostadil; Anidulafungin; Antidiuretic Hormone Receptor Antagonists; Antifungal Agents; Antineoplastic Agents; Arabinonucleosides; Benzazepines; Benzenesulfonates; Drug Approval; Drug Interactions; Drug Monitoring; Drug Therapy; Echinocandins; Fatty Acids; Humans; Hypoglycemic Agents; Immunoconjugates; Immunosuppressive Agents; Indoles; Insulin; Insulin Detemir; Insulin, Long-Acting; Intercellular Signaling Peptides and Proteins; Lenalidomide; Lubiprostone; Niacinamide; Patient Education as Topic; Peptides, Cyclic; Phenylurea Compounds; Piperazines; Pyridines; Pyrroles; Ranolazine; Sorafenib; Sunitinib; Thalidomide; United States | 2007 |